Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) closed at $34.6 down -1.17% from its previous closing price of $35.01. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 2.01 million shares were traded. ARWR stock price reached its highest trading level at $35.65 during the session, while it also had its lowest trading level at $34.47.
Ratios:
For a deeper understanding of Arrowhead Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.87 and its Current Ratio is at 4.87. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 01 ’25 when James Hamilton bought 20,000 shares for $35.00 per share.
Hamilton James C sold 15,000 shares of ARWR for $450,000 on Sep 12 ’25. The Chief Medical Officer now owns 232,122 shares after completing the transaction at $30.00 per share. On Sep 12 ’25, another insider, Hamilton James C, who serves as the Officer of the company, bought 15,000 shares for $30.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 4783711232 and an Enterprise Value of 4596318208. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.35 while its Price-to-Book (P/B) ratio in mrq is 9.15. Its current Enterprise Value per Revenue stands at 8.022 whereas that against EBITDA is -53.824.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.26, which has changed by 0.83846974 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $35.40, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 44.10%, while the 200-Day Moving Average is calculated to be 87.12%.
Shares Statistics:
For the past three months, ARWR has traded an average of 2.46M shares per day and 2457030 over the past ten days. A total of 138.14M shares are outstanding, with a floating share count of 128.34M. Insiders hold about 7.17% of the company’s shares, while institutions hold 74.94% stake in the company. Shares short for ARWR as of 1757894400 were 11862693 with a Short Ratio of 4.82, compared to 1755216000 on 12984322. Therefore, it implies a Short% of Shares Outstanding of 11862693 and a Short% of Float of 11.07.
Earnings Estimates
Arrowhead Pharmaceuticals Inc (ARWR) is currently under the scrutiny of 12.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $0.34, with high estimates of $2.0 and low estimates of -$1.08.
Analysts are recommending an EPS of between $0.82 and -$1.06 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$2.88, with 12.0 analysts recommending between -$0.85 and -$4.55.
Revenue Estimates
For the next quarter, 13 analysts are estimating revenue of $244.26M. There is a high estimate of $468.84M for the next quarter, whereas the lowest estimate is $22.8M.
A total of 15 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $923M, while the lowest revenue estimate was $573M, resulting in an average revenue estimate of $735.77M. In the same quarter a year ago, actual revenue was $3.55MBased on 15 analysts’ estimates, the company’s revenue will be $382.73M in the next fiscal year. The high estimate is $646.8M and the low estimate is $94.3M.
